Belgium-headquartered Galapagos NV (GLPG) on Wednesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to GLPG5101 for the treatment of relapsed/refractory mantle cell lymphoma, an aggressive subtype of non-Hodgkin lymphoma.
The Regenerative Medicine Advanced Therapy (RMAT) designation, established under the U.S. 21st Century Cures Act, is intended to accelerate development and review of promising cell and gene therapies for serious or life-threatening conditions.
GLPG5101 is currently under a Phase 1/2 multicenter study in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and Diffuse large B-cell lymphoma, dubbed ATALANTA-1.
The benefits of the RMAT designation include increased FDA guidance and more frequent interactions during development, eligibility for accelerated approval based on surrogate or intermediate endpoints, all Fast Track and Breakthrough Therapy advantages such as priority review and rolling submissions, and early discussions of potential study endpoints.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.